

Table 2. HRs (95% CIs) for the association of MTHFR genotypes with incident AMD in the Women's Genome Health Study.

	<u>MTHFR 677</u>			P trend	<u>MTHFR 1298</u>			P trend
	CC (n=10,237)	CT (n=9,925)	TT (n=2,611)		AA (n=10,553)	AC (n=9,882)	CC (n=2,338)	
	<u>Total AMD</u>							
Events	184	153	47		178	171	35	
Crude [*]	1.00	0.85 (0.69-1.05)	0.99 (0.72-1.36)	0.46	1.00	1.04 (0.84-1.28)	0.89 (0.62-1.28)	0.76
Multivariate 1 [†]	1.00	0.86 (0.69-1.06)	0.98 (0.70-1.35)	0.44	1.00	1.05 (0.85-1.29)	0.89 (0.62-1.29)	0.81
Multivariate 2 [‡]	1.00	0.85 (0.68-1.06)	0.95 (0.68-1.32)	0.36	1.00	1.05 (0.85-1.30)	0.90 (0.62-1.30)	0.87
	<u>Visually-significant AMD</u>							
Events	80	59	18		62	73	22	
Crude [*]	1.00	0.75 (0.53-1.05)	0.84 (0.50-1.40)	0.20	1.00	1.28 (0.91-1.80)	1.62 (0.99-2.63)	0.04
Multivariate 1 [†]	1.00	0.78 (0.56-1.10)	0.88 (0.53-1.46)	0.30	1.00	1.28 (0.91-1.80)	1.55 (0.94-2.55)	0.054
Multivariate 2 [‡]	1.00	0.78 (0.55-1.09)	0.84 (0.50-1.41)	0.24	1.00	1.29 (0.92-1.82)	1.58 (0.96-2.60)	0.04

Abbreviations: HR, hazard ratio; CI, confidence interval; MTHFR, methylenetetrahydrofolate reductase; AMD, age-related macular degeneration.

^{*} Adjusted for age, randomized treatment assignment (aspirin, vitamin E, beta carotene)

[†] Additionally adjusted for smoking (current, past, never), alcohol use (rarely/never, 1-3 drinks/month, 1-6 drinks/week, and ≥ 1 drinks/day), body mass index (continuous), postmenopausal hormone use, history of hypertension (ever diagnosis by physician or self-reported blood pressure $\geq 140/90$; yes or no), history of hyperlipidemia (baseline history of cholesterol-medication use or a physician diagnosis of high cholesterol or a self-reported cholesterol of at least 240 mg/dL; yes or no), multivitamin use (current, past/never), history of eye exam in the last 2 years.

[‡] Additionally adjusted for homocysteine ($\mu\text{mol/L}$).